Skip to main content

Thermo Fisher to Pay $471M for Brahms

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to acquire German diagnostics firm Brahms for €330 million ($471 million) in a deal that will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.

Privately-held Brahms' flagship product is the procalcitonin biomarker for diagnosis and treatment of sepsis.

Brahms' "assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates promising opportunities to commercialize new patented diagnostic tests," Thermo Fisher President and CEO Marijn Dekkers said in a statement. "In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the US to market innovative new Brahms products, such as PCT and others now in development."

Brahms will be integrated into Thermo Fisher's specialty diagnostics business, which is part of the company's Analytcial Technologies segment. The deal is expected to close later this month.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.